Subscribe
Caroline Ruda / Shutterstock.com
17 June 2025NewsAmericasMarisa Woutersen

Novo Nordisk patent lapse opens door for Canadian Ozempic generics

Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation over whether it was a mistake or calculated move in a country known for strict drug price controls.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Patent cliff: 5 blockbusters running out of road
1 April 2025   MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.
Americas
Novo Nordisk targets Canada’s largest generics maker over diabetes drug
15 October 2024   Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.
Big Pharma
Novo Nordisk’s uphill battle in the counterfeit weight loss craze
12 July 2024   As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.


Editor's picks

UPC confirms permanent injunction against Curio in 10x tech dispute
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025

Editor's picks

Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025

More on this story

Americas
Patent cliff: 5 blockbusters running out of road
1 April 2025   MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.
Americas
Novo Nordisk targets Canada’s largest generics maker over diabetes drug
15 October 2024   Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.
Big Pharma
Novo Nordisk’s uphill battle in the counterfeit weight loss craze
12 July 2024   As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.

More on this story

Americas
Patent cliff: 5 blockbusters running out of road
1 April 2025   MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.
Americas
Novo Nordisk targets Canada’s largest generics maker over diabetes drug
15 October 2024   Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.
Big Pharma
Novo Nordisk’s uphill battle in the counterfeit weight loss craze
12 July 2024   As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.

More features

UPC confirms permanent injunction against Curio in 10x tech dispute
McDermott Will & Emery appoints senior Paris litigator
UK govt sets sights on being AI drug discovery ‘world leader’
UPC promises CMS overhaul with new phased release
Vidal: Coke Morgan Stewart's rulings are 'taxing innovation'
Sheppard Mullin expands practice with Perkins Coie trio
Synthego clears rival’s patents from CRISPR market at Fed Circ
Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies